Lonza licenses rights to sell synthetic AAVs to gene therapy developers

By Gareth Macdonald contact

- Last updated on GMT

iStock/kirstypargeter
iStock/kirstypargeter

Related tags: License

Lonza has licensed rights to synthetic adeno-associated viral (AAV) vectors developed by scientists at US hearing research centre, Massachusetts Eye and Ear.

The agreement – financial terms of which were not provide – gives Lonza rights to license the synthetic vectors – known as Anc-AAVs – and to provide them to customers.

The firm will also fund development of next generation vectors by Luk Vandenberghe, ​assistant Professor at Harvard Medical School and director of the Grousbeck Gene Therapy Center at Massachusetts Eye and Ear.

Massachusetts Eye and Ear ​retains certain commercial and academic rights, including the ability to commercialize self-directed gene therapy programs and all rights in the challenging space of ultra-rare diseases.

Commercial scale production

The most advanced vector is Anc80. Under the deal Lonza will develop commercial scale production processes for Anc80 and future vectors.

The Swiss life sciences firm will undertake the work at the facility it is building in Pearland​, Texas, which is due to become operational next year.

Marc Funk, Lonza’s pharma and biotech COO, said: “This strategic licensing deal with Massachusetts Eye and Ear emphasizes Lonza’s strong commitment to the field of gene therapy and our continuous quest for improving patients’ lives.

Drawing on our licensing expertise, we will be able to leverage our experience as the leading global AAV manufacturer in our broad range of service offerings​.”

Related news

Show more

Related products

show more

Strategies for Upstream Intensification

Strategies for Upstream Intensification

Take the Right Path Upstream with MilliporeSigma | 01-Sep-2020 | Technical / White Paper

The Facility of the Future represents a transformation in how biologics are developed and manufactured.

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 05-Aug-2020 | Technical / White Paper

Traditional methods for adventitious agent testing rely on biological amplification and detection, which can take several weeks. This time-consuming approach...

Related suppliers

Follow us

Products

View more

Webinars